Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
[HTML][HTML] Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review
Y Huang, HJ Cho, BE Stranger… - … Lung Cancer Research, 2022 - ncbi.nlm.nih.gov
Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung
cancer patients: a narrative review - PMC Back to Top Skip to main content NIH NLM Logo …
cancer patients: a narrative review - PMC Back to Top Skip to main content NIH NLM Logo …
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
X Chen, Y Liu, OD Røe, Y Qian, R Guo, L Zhu, Y Yin… - PloS one, 2013 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
[HTML][HTML] Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future
AK Nowak - Annals of cardiothoracic surgery, 2012 - ncbi.nlm.nih.gov
© AME Publishing Company. All rights reserved. Ann Cardiothorac Surg 2012; 1 (4): 508-
515 www. annalscts. com therapy, one year survival and time to progression were very …
515 www. annalscts. com therapy, one year survival and time to progression were very …
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
FS Farhat, W Houhou - Therapeutic advances in medical …, 2013 - journals.sagepub.com
The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has
witnessed a swift evolution. The number of targeted drugs that can improve patient …
witnessed a swift evolution. The number of targeted drugs that can improve patient …
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications
RD Gentzler, JD Patel - Therapeutic advances in medical …, 2014 - journals.sagepub.com
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the
industrialized world. Despite significant progress in early stage disease, survival rates for …
industrialized world. Despite significant progress in early stage disease, survival rates for …
非小细胞肺癌患者血清EGFR 基因突变循环DNA 检测
姜北， 李晶， 巩平 - 中华肿瘤防治杂志, 2014 - cqvip.com
目的: 探讨循环DNA 测定表皮生长因子受体(epidermal growth factor receptor, EGFR)
突变的可行性; 旨在提供更方便, 快捷, 无创的分子生物检测手段, 指导晚期非小细胞肺癌(non …
突变的可行性; 旨在提供更方便, 快捷, 无创的分子生物检测手段, 指导晚期非小细胞肺癌(non …
Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck
The identification of common molecular aberrations that drive cancer progression has led to
targeted therapies that improve treatment efficacy in many tumor types. Epidermal growth …
targeted therapies that improve treatment efficacy in many tumor types. Epidermal growth …
EGFR-TKIs 在晚期非小细胞肺癌靶向治疗中的临床研究
姜北， 李晶， 万鹏， 巩平 - 现代生物医学进展, 2013 - cqvip.com
目的: 探讨EGFR-TKIs 在晚期非小细胞肺癌靶向治疗中的疗效及预后. 方法: 收集本院2009 年~
2011 年经病理学或细胞学确诊的非小细胞肺癌患者92 例, 患者自愿口服EGFR-TKIs 靶向治疗 …
2011 年经病理学或细胞学确诊的非小细胞肺癌患者92 例, 患者自愿口服EGFR-TKIs 靶向治疗 …
吸烟对肺癌患者表皮生长因子影响的Meta 分析
杭欣， 徐兴祥 - 中华肺部疾病杂志: 电子版, 2015 - cqvip.com
目的探讨吸烟对肺癌患者表皮生长因子受体(EGFR) 突变, 表达及其耐药性和临床疗效的影响,
为临床肺癌患者的疗效评估或靶向治疗的优势人群筛选提供依据. 方法计算机检索Pub Med, Pro …
为临床肺癌患者的疗效评估或靶向治疗的优势人群筛选提供依据. 方法计算机检索Pub Med, Pro …